Year 2008,
Volume: 5 Issue: 2, 80 - 83, 01.06.2008
Abstract
Keywords
References
- REFERENCES 1. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensinaldosterone system. N Engl J Med 2004;351: 585-92
- 2. Dahlström U, Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol 1993;71:29A-33A
- 3. van Vilet A, Donker AJM, Nauta JJP, Verheught FW. Spironolactone in congestive heart-fealure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:21A-28A
- 4. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin convertingenzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999;22:17-22
- 5. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldoctone Evulation Study. N Engl J Med 2004;351:543-51
- 6. Mark A, Perazella, MD. Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med 2000;109:307-14
- 7. Simko F, Bada V, Simkova M, Simko J, Kovacs L, Hulin I. The significance of aldosterone in chronic heart failure: the RALES study. Vnitr Lek 2002;48:767-72
- 8. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998;158:917-24
- 9. Ahuja TS, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. 1. Predictors of the development of hyperkalemia in patients using angiotensinconverting enzyme inhibitors. Am J Nephrol 2000;20:268-72
- 10. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensinconverting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438-41
- 11. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther 2005;30:233-9
- 12. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003;18:1814-9
- 13. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atatr D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 2003; 327:1141-2
- 14. The RALES Investigators. Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-907
Year 2008,
Volume: 5 Issue: 2, 80 - 83, 01.06.2008
Abstract
-
Keywords
References
- REFERENCES 1. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensinaldosterone system. N Engl J Med 2004;351: 585-92
- 2. Dahlström U, Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol 1993;71:29A-33A
- 3. van Vilet A, Donker AJM, Nauta JJP, Verheught FW. Spironolactone in congestive heart-fealure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:21A-28A
- 4. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin convertingenzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999;22:17-22
- 5. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldoctone Evulation Study. N Engl J Med 2004;351:543-51
- 6. Mark A, Perazella, MD. Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med 2000;109:307-14
- 7. Simko F, Bada V, Simkova M, Simko J, Kovacs L, Hulin I. The significance of aldosterone in chronic heart failure: the RALES study. Vnitr Lek 2002;48:767-72
- 8. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998;158:917-24
- 9. Ahuja TS, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. 1. Predictors of the development of hyperkalemia in patients using angiotensinconverting enzyme inhibitors. Am J Nephrol 2000;20:268-72
- 10. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensinconverting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438-41
- 11. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther 2005;30:233-9
- 12. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003;18:1814-9
- 13. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atatr D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 2003; 327:1141-2
- 14. The RALES Investigators. Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-907
There are 14 citations in total.
Details
| Primary Language | English |
|---|---|
| Authors | |
| Publication Date | June 1, 2008 |
| IZ | https://izlik.org/JA73JY83WF |
| Published in Issue | Year 2008 Volume: 5 Issue: 2 |